GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » YoY EBITDA Growth

Lumos Diagnostics Holdings (ASX:LDX) YoY EBITDA Growth : 51.61% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Lumos Diagnostics Holdings's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 51.61%.

Lumos Diagnostics Holdings's EBITDA per Share for the six months ended in Dec. 2023 was A$-0.02.

Lumos Diagnostics Holdings YoY EBITDA Growth Historical Data

The historical data trend for Lumos Diagnostics Holdings's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings YoY EBITDA Growth Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23
YoY EBITDA Growth
- 92.23

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial - - 49.18 99.15 51.61

Lumos Diagnostics Holdings YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Lumos Diagnostics Holdings's YoY EBITDA Growth for the fiscal year that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (A: Jun. 2023 )
=(EBITDA per Share (A: Jun. 2023 )-EBITDA per Share (A: Jun. 2022 ))/ | EBITDA per Share (A: Jun. 2022 ) |
=(-0.031--0.399)/ | -0.399 |
=92.23 %

Lumos Diagnostics Holdings's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-0.015--0.031)/ | -0.031 |
=51.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumos Diagnostics Holdings YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Diagnostics Holdings (ASX:LDX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » YoY EBITDA Growth
Comparable Companies
ASX:CTE ASX:GTG ASX:RHY ASX:BDX ASX:IBX ASX:IIQ ASX:GSS ASX:MAP TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH ILMN DGX
Traded in Other Exchanges
LDXHF:USA
Address
2724 Loker Ave West, Carlsbad, CA, USA, 92010
Website
https://www.lumosdiagnostics.com
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.

Lumos Diagnostics Holdings (ASX:LDX) Headlines

No Headlines